Brief description |
Acrizanib (LHA510, LHA-510) is a novel potent, selective VEGFR-2 (KDR) inhibitor with IC50 of 17.4 nM in cell-based assays; exhibits <10% remaining kinase activity against only 13 wildtype kinases, CSF1R, Kit, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, Fms, DDR1, DDR2, TIE1, and ABL1 in a panel of >400 kinases. |